Each treatment year, less than 1% of the men who started the year discontinued Cenforce because of treatment-related adverse events, for a total of only 11 (1.1%) of the original 979 participants over the 4 years of the study ( Table 3 ). Discontinuations were caused by dyspepsia (n = 4), rhinitis (n = 2), abnormal vision plus headache (n = 1), dyspepsia plus rhinitis (n = 1), and flushing, dizziness, and myalgia (n = 1 each). Of the 149 serious adverse events that occurred during the 4 years of the study, including 18 acute myocardial infarctions, none were considered by the investigator to be treatment related. Over the 4-year study period, 37 (3.8%) of the men had 1 or more adverse events that led to changes in dosing or to temporary or permanent discontinuation and were determined by the investigators to be treatment-related ( Table 2 ). Of the 47 events, headache and dyspepsia were most common (n = 10 each), followed by rhinitis (n = 6), flushing (n = 5), abnormal vision (n = 4), dizziness (n = 3), and 1 report each of mild palpitations, moderate tachycardia, diarrhea, nausea, myalgia, hypertonia, respiratory disorder, conjunctivitis, and photophobia.
Â
Men who previously completed and were compliant with Cenforce or placebo treatment in 1 of 4 double-blind, placebo-controlled trials, and subsequently completed and were compliant with Cenforce treatment in initial open-label extension, were eligible for inclusion in this long-term extension study. Our objective was to assess the long-term safety and effectiveness of Cenforce treatment in men with ED. The population included patients with ED of organic and psychogenic etiology and typical concomitant medical conditions for this population (ie, hypertension, diabetes, hyperlipidemia, and a history of ischemic heart disease).Â
For example, 1,358 men with ED completed 1 of 4 double-blind trials and continued with open-label Cenforce treatment in extension studies for a total treatment duration of approximately 1 year ( Morales et al 1998 ; Steers et al 2001 ). In the current study, 979 of these men subsequently received up to 4 more years of open-label, flexible-dose (25, 50, and 100 mg) Cenforce.https://ecenforce.com/it/http://mycenforce.com/fr/